WO2018041112A1 - 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用 - Google Patents

一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用 Download PDF

Info

Publication number
WO2018041112A1
WO2018041112A1 PCT/CN2017/099549 CN2017099549W WO2018041112A1 WO 2018041112 A1 WO2018041112 A1 WO 2018041112A1 CN 2017099549 W CN2017099549 W CN 2017099549W WO 2018041112 A1 WO2018041112 A1 WO 2018041112A1
Authority
WO
WIPO (PCT)
Prior art keywords
methanesulfonamidobenzyl
methoxy
benzyloxy
salt derivative
acid
Prior art date
Application number
PCT/CN2017/099549
Other languages
English (en)
French (fr)
Inventor
谢美华
张福利
吴泰志
钟家亮
Original Assignee
中国医药工业研究总院
上海医药工业研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610786945.XA external-priority patent/CN107793356B/zh
Priority claimed from CN201610786957.2A external-priority patent/CN107778232B/zh
Application filed by 中国医药工业研究总院, 上海医药工业研究院 filed Critical 中国医药工业研究总院
Priority to EP17845414.6A priority Critical patent/EP3508478B1/en
Priority to KR1020197009017A priority patent/KR102346338B1/ko
Priority to US16/329,685 priority patent/US10676442B2/en
Priority to JP2019512752A priority patent/JP6823714B2/ja
Publication of WO2018041112A1 publication Critical patent/WO2018041112A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline salt derivative and preparation thereof And a pharmaceutical composition comprising a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline .
  • SCD Sudden cardiac death
  • Antiarrhythmic drugs can be divided into four categories: Class I is a sodium channel blocker, which has three subtypes a, b, and c. Class Ia is a moderate block of sodium channel, representing the drug Quinidine, etc.; Class Ib is a mild block of sodium channel, which represents the drug beneficial to Lidocaine; Ic class is a significant block of sodium channel, Representative drugs include Flecainide and the like. Class II is a beta adrenergic blocker, and the representative drug is Propranolol. Class III is a drug that selectively prolongs the repolarization process, which prolongs the action potential duration (APD) and the effective refractory period (ERP), and represents a drug such as Amiodarone. Class IV is a calcium antagonist, and the representative drug is Verapamil.
  • Class Ia is a moderate block of sodium channel, representing the drug Quinidine, etc.
  • Class Ib is a mild block of sodium channel, which represents the drug beneficial to Lidocaine
  • Ic class
  • Isoquinoline alkaloids are widely found in natural plants, among which bisbenzylisoquinoline alkaloids (eg, berbamine, dauricine, tetrandrine, xylophylline, neferine), monobenzyl Isoquinoline alkaloids (such as norepinephrine) and protoberberine (Huangliansu) have anti-arrhythmia and other cardiovascular activities.
  • bisbenzylisoquinoline alkaloids eg, berbamine, dauricine, tetrandrine, xylophylline, neferine
  • monobenzyl Isoquinoline alkaloids such as norepinephrine
  • protoberberine Huangliansu
  • berberine exhibits class III antiarrhythmic activity and is clinically reported for the treatment of ventricular arrhythmias.
  • Patent ZL200710181295.7 discloses 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline (SIPI-409) and The structure and preparation method and application of SIPI-409 hydrochloride.
  • the present invention aims to provide a SIPI-409 salt derivative having good solubility in water and a preparation method thereof.
  • the solubility of the salt derivative in water is not less than 3.0 nmol/mL or 1.8 mg/mL.
  • HA is selected from the group consisting of sulfuric acid, phosphoric acid, nicotinic acid, oxalic acid, glycolic acid, benzenesulfonic acid, or orotic acid; and X is selected from 1/3, 1/2, or 1.
  • the salt of 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline is a crystal.
  • HA is sulfuric acid; and X is selected from 1/2 or 1.
  • HA is oxalic acid
  • X is selected from 1/2 or 1.
  • the crystal form of the crystal is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 4.9 ⁇ 0.2 °, 7.1 ⁇ 0.2 °, 8.4 ⁇ 0.2 °, 9.7 ⁇ 0.2 °, 12.0 ⁇ 0.2 °, 15.4 ⁇ 0.2 °, 17.0 ⁇ 0.2 °, 19.5 ° ⁇ 0.2 °, 20.3 ⁇ 0.2 °, 20.9 ⁇ 0.2 °, 21.6 ⁇ 0.2°, 22.8 ⁇ 0.2°, 23.6 ⁇ 0.2°, 24.6 ⁇ 0.2°, 25.4 ⁇ 0.2°, 26.0 ⁇ 0.2°, 30.8 ⁇ 0.2°; or in DSC spectra when analyzed by differential scanning calorimetry (DSC) There is an endothermic peak at 130 ⁇ 5 °C.
  • DSC differential scanning calorimetry
  • the crystal form of the crystal is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 4.6 ⁇ 0.2 °, 7.6 ⁇ 0.2 °, 9.8 ⁇ 0.2 °, 10.2 ⁇ 0.2 °, 13.9 ⁇ 0.2 °, 14.4 ⁇ 0.2 °, 15.3 ⁇ 0.2 °, 18.1 ⁇ 0.2 °, 16.8 ⁇ 0.2 °, 20.5 ⁇ 0.2 °, 20.9 ⁇ 0.2 °, 21.9 ⁇ 0.2 °, 23.1 ⁇ 0.2 °, 23.5 ⁇ 0.2 °, 24.3 ⁇ 0.2 °, 27.1 ⁇ 0.2 °; more preferably, the X-powder diffraction pattern of the crystal is shown in Figure 1.
  • the crystal form of the crystal when HA is nicotinic acid is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 5.0 ⁇ 0.2 °, 5.9 ⁇ 0.2 °, 7.2 ⁇ 0.2 °, 8.2 ⁇ 0.2 °, 10.9 ⁇ 0.2 °, 12.2 ⁇ 0.2 °, 13.4 ⁇ 0.2 °, 14.4 ° ⁇ 0.2 °, 15.1 ⁇ 0.2 °, 15.5 ⁇ 0.2°, 17.0 ⁇ 0.2°, 17.4 ⁇ 0.2°, 17.8 ⁇ 0.2°, 18.7 ⁇ 0.2°, 19.9 ⁇ 0.2°, 20.5 ⁇ 0.2°, 20.8 ⁇ 0.2°, 21.9 ⁇ 0.2°, 23.1 ⁇ 0.2°, 23.5 ⁇ 0.2 °, 24.8 ⁇ 0.2 °, 25.1 ⁇ 0.2 °, 25.6 ⁇ 0.2 °, 27.0 ⁇ 0.2 °, 27.6
  • the crystal form of the crystal is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 3.4 ⁇ 0.2 °, 4.6 ⁇ 0.2 °, 5.5 ⁇ 0.2 °, 7.8 ⁇ 0.2 °, 9.2 ⁇ 0.2 °, 10.2 ⁇ 0.2 °, 10.8 ⁇ 0.2 °, 11.9 ° ⁇ 0.2 °, 13.1 ⁇ 0.2 °, 13.8 ⁇ 0.2 °, 14.6 ⁇ 0.2°, 16.4 ⁇ 0.2°, 17.0 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.0 ⁇ 0.2°, 20.2 ⁇ 0.2°, 21.9 ⁇ 0.2°, 23.6 ⁇ 0.2°, 25.8 ⁇ 0.2°, 27.3 ⁇ 0.2°, 30.0 ⁇ 0.2°, 31.9 ⁇ 0.2°; or when analyzed by differential scanning calorimetry (DSC), there is an endother
  • the crystal form of the crystal when HA is glycolic acid is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 4.7 ⁇ 0.2 °, 7.5 ⁇ 0.2 °, 9.9 ⁇ 0.2 °, 10.3 ⁇ 0.2 °, 13.7 ⁇ 0.2 °, 14.3 ⁇ 0.2 °, 14.9 ⁇ 0.2 °, 15.3 ° ⁇ 0.2 °, 16.1 ⁇ 0.2 °, 16.9 ⁇ 0.2 °, 17.6 ⁇ 0.2 °, 18.1 ⁇ 0.2°, 18.9 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.4 ⁇ 0.2°, 20.8 ⁇ 0.2°, 21.8 ⁇ 0.2°, 22.5 ⁇ 0.2°, 22.9 ⁇ 0.2°, 24.3 ⁇ 0.2°, 24.9 ⁇ 0.2°, 25.3 ⁇ 0.2°, 25.9 ⁇ 0.2°, 27.7 ⁇ 0.2°; or when analyzed by differential scanning calorimetry (XRPD)
  • the crystal form of the crystal when HA is benzenesulfonic acid is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 6.1 ⁇ 0.2 °, 6.8 ⁇ 0.2°, 8.2 ⁇ 0.2°, 8.8 ⁇ 0.2°, 11.5 ⁇ 0.2°, 12.7 ⁇ 0.2°, 14.4 ⁇ 0.2°, 15.0° ⁇ 0.2°, 15.5 ⁇ 0.2°, 16.5 ⁇ 0.2°, 17.0 ⁇ 0.2°, 17.4 ⁇ 0.2°, 17.7 ⁇ 0.2°, 18.7 ⁇ 0.2°, 19.4 ⁇ 0.2°, 19.8 ⁇ 0.2°, 20.3 ⁇ 0.2°, 21.3 ⁇ 0.2°, 21.7 ⁇ 0.2°, 22.6 ⁇ 0.2°, 23.0 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.2 ⁇ 0.2°, 29.1 ⁇ 0.2°; or when analyzed by differential scanning calorimetry (DSC), there is an endothermic peak in the DSC spectrum at 150 ⁇ 5°C, and there is an endother
  • the crystal form of the crystal when HA is orotic acid is determined by X-ray diffraction technique (XRPD) and characterized by a Bragg 2 Theta angle (Bragg 2-Theta) as follows: 5.8 ⁇ 0.2 °, 8.7 ⁇ 0.2°, 9.9 ⁇ 0.2°, 11.2 ⁇ 0.2°, 12.5 ⁇ 0.2°, 13.9 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.2° ⁇ 0.2°, 16.2 ⁇ 0.2°, 17.0 ⁇ 0.2°, 17.4 ⁇ 0.2°, 17.8 ⁇ 0.2°, 18.7 ⁇ 0.2°, 19.0 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.9 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.0 ⁇ 0.2°, 24.9 ⁇ 0.2°, 25.9 ⁇ 0.2°, 27.6 ⁇ 0.2°, 29.5 ⁇ 0.2°, 31.0 ⁇ 0.2°, 31.4 ⁇ 0.2°; or one in the DSC spectrum when analyzed by differential scanning calorimetry (DSC) The endothermic peak is at 138 ⁇ 5 °C.
  • DSC differential scanning calori
  • a 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3 provided by the invention as described above a method for producing a salt derivative of 4-tetrahydroisoquinoline, which comprises: 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3 , 4-tetrahydroisoquinoline is reacted with the corresponding acid HA to form a salt derivative.
  • the preparation method comprises: 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2 provided by the present invention as described above.
  • the 3,4-tetrahydroisoquinoline is reacted with the corresponding acid in an organic solvent to form a salt derivative.
  • the preparation method comprises: 1-(3-methanesulfonamidobenzyl)-6- when HA is nicotinic acid, oxalic acid, glycolic acid, benzenesulfonic acid, or orotic acid.
  • HA nicotinic acid
  • oxalic acid glycolic acid
  • benzenesulfonic acid or orotic acid.
  • the methoxy group, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline is dissolved in an organic solvent, and then the corresponding acid is added, and after cooling, it is crystallized to give a product.
  • the preparation method comprises: 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1, when HA is sulfuric acid or phosphoric acid, The 2,3,4-tetrahydroisoquinoline is dissolved in an organic solvent, and then an organic solvent containing the corresponding acid is added, and after cooling, it is crystallized to obtain a product.
  • the preparation method further comprises washing and drying the precipitated crystals or precipitate.
  • reaction temperature of the reaction is from 0 to 80 °C.
  • the organic solvent is methanol, ethanol, isopropanol, acetone, 2-butanone, methyl acetate, isopropyl acetate, methyl tertiary ether acetonitrile, or toluene.
  • the reaction temperature is from 10 to 60 ° C; more preferably 40 ° C.
  • a pharmaceutical composition comprising an effective amount of 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyl provided by the invention as described above A salt derivative of oxy-1,2,3,4-tetrahydroisoquinoline and one or more pharmaceutically acceptable excipients.
  • a 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3 provided by the invention as described above.
  • a salt derivative of 4-tetrahydroisoquinoline for use in the preparation of an antiarrhythmic drug.
  • the present invention provides a salt derivative of a corresponding compound which is soluble in water, thereby improving its bioavailability and improving its medicinal properties.
  • Figure 1 shows the XRPD pattern of SIPI-409 phosphate crystal under the experimental conditions of Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 2 is a DSC pattern of SIPI-409 phosphate crystal; the downward direction peak is indicated as an endothermic peak.
  • Figure 3 is an XRPD pattern of SIPI-409 sulfate crystal under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 4 is a DSC pattern of SIPI-409 sulfate crystal; wherein the downward direction peak is represented as an endothermic peak.
  • Figure 5 is an XRPD pattern of SIPI-409 nicotinate crystal under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 6 is a DSC pattern of SIPI-409 nicotinate crystals; wherein the downward direction peak is represented as an endothermic peak.
  • Figure 7 is an XRPD pattern of SIPI-409 oxalate crystal under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 8 is a DSC pattern of SIPI-409 oxalate crystal; wherein the downward direction peak is represented as an endothermic peak.
  • Figure 9 is an XRPD pattern of SIPI-409 glycolate crystal under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 10 is a DSC chart of SIPI-409 glycolate crystals; wherein the downward direction peak is represented as an endothermic peak.
  • Figure 11 is an XRPD pattern of SIPI-409 besylate crystal under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 12 is a DSC chart of SIPI-409 besylate crystals; wherein the downward direction peak is represented as an endothermic peak.
  • Figure 13 is an XRPD pattern of SIPI-409 orotate crystals under experimental conditions using a Cu target radiation source; the horizontal axis is the diffraction peak position (2 ⁇ value) and the vertical axis is the diffraction peak intensity.
  • Figure 14 is a DSC spectrum of SIPI-409 orotate crystal; wherein the downward direction peak is expressed as Endothermic peak.
  • Figure 15 is a comparison of the XRPD pattern of SIPI-409 reacted with 14 acids and the XRPD pattern of SIPI-409 material;
  • A is an XRPD pattern of the SIPI-409 starting material and an XRPD pattern of the reaction product with hydrochloric acid;
  • B is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the reaction product of succinic acid;
  • C is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with glycolic acid;
  • D is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the oxalic acid reaction product;
  • E is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with orotate;
  • F is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with fumaric acid;
  • G is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with tartaric acid;
  • H is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the reaction product of ethanedisulfonic acid;
  • I is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the malic acid reaction product;
  • J is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with hydrobromic acid;
  • K is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the phosphoric acid reaction product
  • L is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with niacin;
  • M is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern with the sulfuric acid reaction product;
  • N is the XRPD pattern of the SIPI-409 starting material and its XRPD pattern of the reaction product with benzenesulfonic acid.
  • Figure 16 is a perspective view showing the stereostructure of a single crystal molecule of SIPI-409 sulfate crystal.
  • Figure 17 is a solubility standard curve obtained using the SIPI-409 standard; R value 0.999932.
  • Figure 18 is an XRPD pattern obtained by examining the crystal stability of various salt derivatives of SIPI-409;
  • A is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 phosphate
  • B is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 nicotinate
  • C is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 glycolate
  • D is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 oxalate
  • E is the XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 orotate
  • F is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 besylate
  • G is an XRPD pattern obtained by examining the stability of the crystal form of SIPI-409 sulfate.
  • the inventors have extensively and intensively studied to find 1-(3-methanesulfonamidobenzyl)-6-methoxy, 7-benzyloxy-1,2,3,4 as shown in formula I.
  • the solubility of the tetrahydroisoquinoline salt derivative in water is significantly improved compared to the existing SIPI-409 and SIPI-409 hydrochloride, and further pharmacokinetic experiments indicate the salt derivatization of SIPI-409 of the present invention.
  • the bioavailability of the material is significantly improved compared to the existing SIPI-409 hydrochloric acid. Taking phosphate as an example, its bioavailability can be increased by 329% compared with the existing SIPI-409 hydrochloride.
  • the present invention provides a salt derivative of the compound SIPI-409 as shown in the formula (I).
  • the salt formed with SIPI-40 may be a common organic or inorganic acid; it may be selected from the acids described in Table 1.
  • XRPD was used to test the results of the salt-type preliminary screening experiment.
  • SIPI-409 was combined with hydrochloric acid, succinic acid, fumaric acid, L-tartaric acid, ethanedisulfonic acid, glycolic acid, orotic acid, DL-malic acid.
  • the XRPD pattern after the reaction of hydrobromic acid, oxalic acid, phosphoric acid, nicotinic acid, sulfuric acid, benzenesulfonic acid and the like was compared with the XRPD pattern of the SIPI-409 raw material, and the results are shown in Fig. 15.
  • phosphoric acid, sulfuric acid, nicotinic acid, oxalic acid, glycolic acid, benzenesulfonic acid, or orotic acid is salted with SIPI-409; more preferred is sulfuric acid, phosphoric acid, nicotinic acid, or oxalic acid.
  • the SIPI-409 phosphate crystal provided by the invention, wherein the ratio of SIPI-409 to phosphoric acid is 1:1, 2:1 or 3:1, when the ratio of SIPI-409 to phosphoric acid is 1:1, the crystal powder X- is obtained.
  • Ray diffraction analysis when using Cu target radiation source experimental conditions, its 2 ⁇ characteristic diffraction peaks are: 4.6 ⁇ 0.2 °, 7.6 ⁇ 0.2 °, 9.8 ⁇ 0.2 °, 10.2 ⁇ 0.2 °, 13.9 ⁇ 0.2 °, 14.4 ⁇ 0.2 °, 15.3 ⁇ 0.2°, 18.1 ⁇ 0.2°, 16.8 ⁇ 0.2°, 20.5 ⁇ 0.2°, 20.9 ⁇ 0.2°, 21.9 ⁇ 0.2°, 23.1 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.3 ⁇ 0.2°, 27.1 ⁇ 0.2°; More preferably, its XRPD pattern is shown in Figure 1.
  • the SIPI-409 sulfate crystal provided by the invention wherein the ratio of SIPI-409 to sulfuric acid is 1:1, 2:1, wherein when the ratio of SIPI-409 to sulfuric acid is 1:1, the powder is obtained by powder X-ray diffraction analysis.
  • the 2 ⁇ characteristic diffraction peaks are: 4.9 ⁇ 0.2°, 7.1 ⁇ 0.2°, 8.4 ⁇ 0.2°, 9.7 ⁇ 0.2°, 12.0 ⁇ 0.2°, 15.4 ⁇ 0.2°, 17.0 ⁇ 0.2.
  • the above SIPI-409 sulfate crystal when analyzed by differential scanning calorimetry (DSC), exhibits an endothermic peak at 130 ⁇ 5 ° C in the DSC spectrum at a heating rate of 10 ° C / min; more preferably, Its DSC spectrum is shown in Figure 4.
  • the single crystal of the above SIPI-409 sulfate crystal (C 25 H 28 N 2 O 4 S ⁇ H 2 SO 4 ) is a colorless transparent block, has a crystal density of 1.361 g/cm 3 , and a space group of P-1, a unit cell.
  • the SIPI-409 nicotinate crystal provided by the invention uses powder X-ray diffraction analysis, and the 2 ⁇ characteristic diffraction peaks of the Cu target radiation source are: 5.0 ⁇ 0.2°, 5.9 ⁇ 0.2°, 7.2 ⁇ 0.2°.
  • the SIPI-409 nicotinate crystal provided by the present invention is analyzed by differential scanning calorimetry (DSC), and exhibits an endothermic peak at 152 ⁇ 5 ° C in the DSC spectrum with a heating rate of 10 ° C/min; More preferably, its DSC pattern is shown in Figure 6.
  • DSC differential scanning calorimetry
  • the invention provides SIPI-409 oxalate crystal, wherein the ratio of SIPI-409 to oxalic acid is 1:1 or 2:1, wherein when the ratio of SIPI-409 to oxalic acid is 1:1, the powder is obtained by powder X-ray diffraction.
  • the above SIPI-409 oxalate crystals were analyzed by differential scanning calorimetry (DSC), and there was an endothermic peak in the DSC spectrum with a heating rate of 10 ° C/min at 161 ⁇ 5 ° C, and at 190 There is a broad endothermic peak in the range of -210 ° C; more preferably, its DSC spectrum is shown in FIG.
  • the SIPI-409 glycolate crystal provided by the invention uses powder X-ray diffraction analysis, and adopts the Cu target radiation source experimental condition, and the 2 ⁇ characteristic diffraction peaks are: 4.7 ⁇ 0.2°, 7.5 ⁇ 0.2°, 9.9 ⁇ 0.2°.
  • the SIPI-409 glycolate crystal provided by the present invention is analyzed by differential scanning calorimetry (DSC), and an endothermic peak exists in the DSC spectrum with a heating rate of 10 ° C/min at 187 ⁇ 5 ° C; More preferably, its DSC pattern is shown in FIG.
  • the SIPI-409 besylate crystal provided by the invention adopts powder X-ray diffraction analysis, and when the experimental conditions of the Cu target radiation source are used, the 2 ⁇ characteristic diffraction peaks are: 6.1 ⁇ 0.2°, 6.8 ⁇ 0.2°, 8.2 ⁇ 0.2.
  • the SIPI-409 besylate crystal provided by the present invention is analyzed by differential scanning calorimetry (DSC), and the DSC spectrum having a heating rate of 10 ° C/min has an endothermic peak at 150 ⁇ 5 ° C. And there is a shoulder near 160 ° C; more preferably, its DSC spectrum is shown in FIG.
  • the SIPI-409 orotate crystal provided by the invention adopts powder X-ray diffraction analysis, and the experimental results of the Cu target radiation source have the 2 ⁇ characteristic diffraction peaks of 5.8 ⁇ 0.2°, 8.7 ⁇ 0.2°, and 9.9 ⁇ 0.2.
  • the SIPI-409 orotate crystal provided by the present invention uses differential scanning calorimetry (DSC) At the time of analysis, there was an endothermic peak in the DSC spectrum showing a heating rate of 10 ° C/min at 138 ⁇ 5 ° C; more preferably, its DSC spectrum is shown in FIG.
  • the SIPI-409 salt derivative crystals to which the present invention relates include single crystals, as well as polymorphs thereof.
  • the invention also provides a salt derivative of SIPI-409 and a preparation method thereof, wherein SIPI-409 is dissolved in an organic solvent, an organic or inorganic acid is added, and after stirring, the crystal is cooled and crystallized to obtain a salt of SIPI-409. Derivative crystals.
  • the solvent described above includes an alcohol solvent, a ketone solvent, an ether solvent, an ester solvent, an aromatic hydrocarbon solvent, and a nitrile solvent.
  • the alcohol solvent includes methanol, ethanol, and isopropanol; preferably methanol; the ketone solvent includes acetone and 2-butanone; and the ether solvent includes methyl tertiary ether, tetrahydrofuran, and 2 methyltetrahydrofuran;
  • the ester solvent includes ethyl acetate, methyl acetate, and isopropyl acetate; the aromatic hydrocarbon solvent includes toluene and xylene; and the nitrile solvent is acetonitrile.
  • the reaction temperature for salt formation is from 0 to 80 ° C; preferably from 10 to 60 ° C; most preferably 40 ° C.
  • the ratio of SIPI-409 to acid and the manner of addition can be adapted to the desired salt derivative without departing from the principles of the invention.
  • the SIPI-409 salt derivative or the crystal thereof provided by the invention has certain stability, and can be used as an active ingredient to develop an oral dosage form anti-arrhythmia drug for clinical use.
  • Common oral administration forms include ordinary tablets, capsules, dispersible tablets, pellets, etc. Excipients, lubricants, binders and the like described in the above dosage forms are all common excipients in the field.
  • the main advantage of the present invention is that the novel SIPI-409 salt derivative and crystal thereof provided by the invention can significantly improve the water solubility thereof, thereby improving the bioavailability and the drug-forming property.
  • the XRPD pattern in the experiment involved in the present invention was obtained under the experimental conditions using a Cu target radiation source.
  • the DSC pattern was expressed as a map at a temperature elevation rate of 10 ° C/min.
  • the stability of the SIPI-40 salt derivative according to the present invention means the temperature, humidity, light stability and hygroscopicity of the salt derivative crystals over a certain period of time.
  • SIPI-409 0.5g (0.11mmol), put it into a 50mL flask, add 20mL methanol solvent, control the temperature of the water bath to 40 ° C, add 1M phosphate methanol solution 1.3mL (0.13mmol), continue to maintain 40 ° C and stir for 2 hours.
  • SIPI-409 0.5g (0.11mmol), place it in a 50mL flask, add 20mL methanol solvent, control the temperature of the water bath at 40 °C, add 1.3M (0.13mmol) of 1M sulfuric acid methanol solution, continue After stirring at 40 ° C for 2 hours, it was cooled to 5 to 15 ° C for crystallization, and filtered to obtain 0.54 g of SIPI-409 sulfate white solid powder in a yield of 90%.
  • SIPI-409: sulfuric acid 1:1 in the crystal, single The crystal data is as shown in the drawing. Its XRPD spectrum is shown in Figure 3, and the DSC spectrum is shown in Figure 4.
  • SIPI-409 0.5g (0.11mmol), put it in a 50mL flask, add 20mL methanol solvent, control the temperature of the water bath to 40 ° C, add 0.205g (0.13mmol) of benzenesulfonic acid, continue to stir at 40 ° C for 2 hours, then cool to Crystallization was carried out at 5 to 15 ° C, and filtration was carried out to obtain 0.57 g of SIPI-409 besylate white solid powder, yield 84%. Its XRPD pattern is shown in Figure 11, and the DSC spectrum is shown in Figure 12.
  • SIPI-409 0.5g (0.11mmol), place it in a 50mL flask, add 20mL methanol solvent, control the temperature of the water bath at 40 ° C, add 0.226g (0.13mmol) of orotate monohydrate, continue to stir at 40 ° C for 2 hours. The mixture was cooled to 5 to 15 ° C for crystallization, and filtered to obtain 0.52 g of a SIPI-409 orotate white solid powder, yield 77%.
  • the XRPD pattern is shown in Figure 13, and the DSC spectrum is shown in Figure 14.
  • Sample treatment The sample to be tested is made into a supersaturated aqueous solution (suspension), shaken at 30 ° C for 12 h, placed in the ultrasound system for 30 s, filtered, diluted by appropriate multiples, and analyzed by HPLC. The test results are shown in Table 3.
  • the results show that the SIPI-409 phosphate, SIPI-409 sulfate, SIPI-409 nicotinate, SIPI-409 oxalate, SIPI-409 glycolate, SIPI-409 besylate, SIPI-409 of the present invention are shown.
  • the solubility of orotate in water is significantly improved over existing SIPI-409 and SIPI-409 hydrochlorides.
  • solubility test results in water show that the solubility of SIPI-409 phosphate in water is greatly improved compared with SIPI-409 and SIPI-409 hydrochloride, so further study on the pharmacokinetics of SIPI-409 phosphate, and SIPI-409 hydrochloride was compared.
  • SIPI-409 hydrochloride and SIPI-409 phosphate were administered orally (PO), and their pharmacokinetic parameters and bioavailability in SD rats were studied.
  • concentrations of SIPI-409 hydrochloride and SIPI-409 phosphate in plasma were determined by liquid chromatography-mass spectrometry-mass spectrometry.
  • the obtained plasma concentration data were calculated using the pharmacokinetic processing software WinNonlin 5.2 non-compartment model to calculate the relevant pharmacokinetic parameters.
  • SIPI-409 phosphate, nicotinate, glycolate, oxalate, orotate, benzenesulfonate, sulphate were placed in an oven at 60 ° C for 0 days, 5 days, 10 days, 20 days , 30 days sampling for XRPD testing.
  • SIPI-409 phosphate, nicotinate, glycolate, oxalate, orotate, benzenesulfonate, sulfate were placed in 92.5% RH (saturated KNO 3 ) for 0 days, 5 days, respectively. Samples were taken for XRPD testing for 10 days, 20 days, and 30 days.
  • SIPI-409 phosphate, nicotinate, glycolate, oxalate, orotate, benzenesulfonate, sulfate are placed in the light box, respectively, on 0 days, 5 days, 10 days, 20 days, 30 days sampling for XRPD test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种如式I所示的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物：所述盐衍生物在水中的溶解度不小于3.0nmol/mL或1.8mg/mL。

Description

一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用 技术领域
本发明涉及一种1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物及其制备方法，以及包含1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的药物组分。
背景技术
突发性心脏死亡(SCD)是心血管疾病死亡的主要原因之一。SCD产生是由于心肌电生理不稳定而导致有规律的心律消失，最严重的是持续室速(VT,ventricular tachycardia)和室颤(VF,vetricalar fibrillation)。
抗心律失常药可分为四类：I类为钠通道阻滞药，其中有a、b、c三个亚类。Ia类为适度阻滞钠通道，代表药物有奎尼丁(Quinidine)等；Ib类为轻度阻滞钠通道，代表药物有利多卡因(Lidocaine)等；Ic类为明显阻滞钠通道，代表药物有氟卡尼(Flecainide)等。II类为β肾上腺素受体阻滞药，代表药物为普萘洛尔(Propranolol)。III类为选择地延长复极过程的药，其延长动作电位时程(APD)及有效不应期(ERP)，代表药物有胺碘酮(Amiodarone)等。IV类为钙拮抗药，代表药物有维拉帕米(Verapamil)等。
异喹啉生物碱广泛存在于天然植物中，其中双苄基异喹啉类生物碱(如：小檗胺、蝙蝠葛碱、粉防己碱、木防己碱、甲基莲心碱)，单苄基异喹啉生物碱(如：去甲乌药碱)和原小檗碱(黄莲素)等均有抗心律失常等心血管活性。其中，小檗碱呈现III类抗心律失常活性，临床报道用于治疗室性心律失常。
上海医药工业研究院谢美华研究员自1985年开始，以去甲乌药碱和小檗碱为先导化合物进行结构改造，设计并合成了近千个衍生物。合成的上述近千个新化合物经抗心律失常有关的药效学筛选试验、Ames毒性试验及急性毒性评价、结合药代参数评估，筛选出最佳的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉(以下用简称SIPI-409)作为候选抗心律失常新药进行临床前开发，其结构如式(II)所示。
Figure PCTCN2017099549-appb-000001
专利ZL200710181295.7公开了1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉(SIPI-409)及SIPI-409盐酸盐的结构及制备方法和应用。
然而在进一步的研究中发现，SIPI-409及SIPI-409盐酸盐在水中的溶解度很低，分别为仅为0.07mg/mL(0.15nmol/mL)和0.51mg/mL(1.05nmol/mL)。同时初步的药代动力学结果表明：注射给药SIPI-409盐酸盐的t1/2与索他洛尔相仿，SD大鼠口服给药生物利用度SIPI-409盐酸盐为24％，远低于索他洛尔(70％)，为SIPI-409盐酸盐在水中溶解度过低所致。
因此，本领域迫切需要提供在水中溶解度好的相应化合物的盐衍生物，进而改善其生物利用度，提高其成药性。
发明内容
本发明旨在提供一种在水中溶解度较好的SIPI-409盐衍生物及其制备方法。
在本发明的第一方面，提供了式I所示的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物：
Figure PCTCN2017099549-appb-000002
所述盐衍生物在水中的溶解度不小于3.0nmol/mL或1.8mg/mL。
在另一优选例中，HA选自硫酸、磷酸、烟酸、草酸、乙醇酸、苯磺酸、或乳清酸；X选自1/3、1/2、或1。
在另一优选例中，所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物为晶体。
在另一优选例中，HA为硫酸；X选自1/2或1。
在另一优选例中，HA为草酸；X选自1/2或1。
在另一优选例中，当HA为硫酸、X为1时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.9±0.2°、7.1±0.2°、8.4±0.2°、9.7±0.2°、12.0±0.2°、15.4±0.2°、17.0±0.2°、19.5°±0.2°、20.3±0.2°、20.9±0.2°、21.6±0.2°、22.8±0.2°、23.6±0.2°、24.6±0.2°、25.4±0.2°、26.0±0.2°、30.8±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在130±5℃处。
在另一优选例中，当X为1、HA为磷酸时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.6±0.2°、7.6±0.2°、9.8±0.2°、10.2±0.2°、13.9±0.2°、14.4±0.2°、15.3±0.2°、18.1±0.2°、16.8±0.2°、20.5±0.2°、20.9±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.3±0.2°、27.1±0.2°；更佳地，所述晶体的X-粉末衍射图谱如图1所示。
在另一优选例中，当X为1、HA为磷酸时，所述晶体使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在201±5℃处；更佳地，所述晶体的DSC图谱如图2所示。
在另一优选例中，当HA为烟酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：5.0±0.2°、5.9±0.2°、7.2±0.2°、8.2±0.2°、10.9±0.2°、12.2±0.2°、13.4±0.2°、14.4°±0.2°、15.1±0.2°、 15.5±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.9±0.2°、20.5±0.2°、20.8±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.8±0.2°、25.1±0.2°、25.6±0.2°、27.0±0.2°、27.6±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在152±5℃。
在另一优选例中，当HA为草酸、X为1时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：3.4±0.2°、4.6±0.2°、5.5±0.2°、7.8±0.2°、9.2±0.2°、10.2±0.2°、10.8±0.2°、11.9°±0.2°、13.1±0.2°、13.8±0.2°、14.6±0.2°、16.4±0.2°、17.0±0.2°、18.4±0.2°、19.0±0.2°、20.2±0.2°、21.9±0.2°、23.6±0.2°、25.8±0.2°、27.3±0.2°、30.0±0.2°、31.9±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在在161±5℃处，且在190～210℃范围存在一个较宽的吸热峰。
在另一优选例中，当HA为乙醇酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.7±0.2°、7.5±0.2°、9.9±0.2°、10.3±0.2°、13.7±0.2°、14.3±0.2°、14.9±0.2°、15.3°±0.2°、16.1±0.2°、16.9±0.2°、17.6±0.2°、18.1±0.2°、18.9±0.2°、19.3±0.2°、20.4±0.2°、20.8±0.2°、21.8±0.2°、22.5±0.2°、22.9±0.2°、24.3±0.2°、24.9±0.2°、25.3±0.2°、25.9±0.2°、27.7±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在187±5℃处。
在另一优选例中，当HA为苯磺酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：6.1±0.2°、6.8±0.2°、8.2±0.2°、8.8±0.2°、11.5±0.2°、12.7±0.2°、14.4±0.2°、15.0°±0.2°、15.5±0.2°、16.5±0.2°、17.0±0.2°、17.4±0.2°、17.7±0.2°、18.7±0.2°、19.4±0.2°、19.8±0.2°、20.3±0.2°、21.3±0.2°、21.7±0.2°、22.6±0.2°、23.0±0.2°、23.5±0.2°、24.2±0.2°、29.1±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在150±5℃处，且在160℃附近存在一个肩峰。
在另一优选例中，当HA为乳清酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：5.8±0.2°、8.7±0.2°、9.9±0.2°、11.2±0.2°、12.5±0.2°、13.9±0.2°、14.1±0.2°、15.2°±0.2°、16.2±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.0±0.2°、20.4±0.2°、21.9±0.2°、23.5±0.2°、24.0±0.2°、24.9±0.2°、25.9±0.2°、27.6±0.2°、29.5±0.2°、31.0±0.2°、31.4±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个 吸热峰在138±5℃处。
在本发明的第二方面，提供了一种如上所述的本发明提供的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其包括：将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉与相应的酸HA反应形成盐衍生物。
在另一优选例中，所述制备方法包括：将如上所述的本发明提供的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉与相应的酸在有机溶剂中反应形成盐衍生物。
在另一优选例中，所述的制备方法包括：HA为烟酸、草酸、乙醇酸、苯磺酸、或乳清酸时，将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉溶解于有机溶剂，然后加入相应的酸，冷却后析晶得产物。
在另一优选例中，所述的制备方法包括：当HA为硫酸或磷酸时，将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉溶解于有机溶剂，然后加入含有相应酸的有机溶剂，冷却后析晶得产物。
在另一优选例中，所述制备方法还包括：将析出的结晶或沉淀洗涤、干燥。
在另一优选例中，所述反应的反应温度为0-80℃。
在另一优选例中，所述有机溶剂为甲醇、乙醇、异丙醇、丙酮、2-丁酮、乙酸甲酯、乙酸异丙脂、甲叔醚乙腈、或甲苯。
在另一优选例中，HA为磷酸时，所述反应温度为10-60℃；更优选为40℃。
在本发明的第三方面，提供了一种药物组合物，由有效量的如上所述的本发明提供的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物和一种或多种药学上可接受的辅料组成。
在本发明的第四方面，提供了一种如上所述的本发明提供的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，在制备抗心律失常的药物中的应用。
据此，本发明提供了一种在水中溶解度好的相应化合物的盐衍生物，进而改善其生物利用度，提高其成药性。
附图说明
图1为SIPI-409磷酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图2为SIPI-409磷酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图3为SIPI-409硫酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图4为SIPI-409硫酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图5为SIPI-409烟酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图6为SIPI-409烟酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图7为SIPI-409草酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图8为SIPI-409草酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图9为SIPI-409乙醇酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图10为SIPI-409乙醇酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图11为SIPI-409苯磺酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图12为SIPI-409苯磺酸盐晶体的DSC图谱；其中方向朝下的峰表示为吸热峰。
图13为SIPI-409乳清酸盐晶体在采用Cu靶辐射光源实验条件下的XRPD图谱；图中横轴为衍射峰位置(2θ值)，纵轴为衍射峰强度。
图14为SIPI-409乳清酸盐晶体的DSC图谱；其中方向朝下的峰表示为 吸热峰。
图15为SIPI-409与14种酸反应后的XRPD图谱与SIPI-409原料的XRPD图谱的比较；其中，
A是SIPI-409原料的XRPD图谱及其与盐酸反应产物的XRPD图谱；
B是SIPI-409原料的XRPD图谱及其与丁二酸反应产物的XRPD图谱；
C是SIPI-409原料的XRPD图谱及其与乙醇酸反应产物的XRPD图谱；
D是SIPI-409原料的XRPD图谱及其与草酸反应产物的XRPD图谱；
E是SIPI-409原料的XRPD图谱及其与乳清酸反应产物的XRPD图谱；
F是SIPI-409原料的XRPD图谱及其与反丁烯二酸反应产物的XRPD图谱；
G是SIPI-409原料的XRPD图谱及其与酒石酸反应产物的XRPD图谱；
H是SIPI-409原料的XRPD图谱及其与乙二磺酸反应产物的XRPD图谱；
I是SIPI-409原料的XRPD图谱及其与苹果酸反应产物的XRPD图谱；
J是SIPI-409原料的XRPD图谱及其与氢溴酸反应产物的XRPD图谱；
K是SIPI-409原料的XRPD图谱及其与磷酸反应产物的XRPD图谱；
L是SIPI-409原料的XRPD图谱及其与烟酸反应产物的XRPD图谱；
M是SIPI-409原料的XRPD图谱及其与硫酸反应产物的XRPD图谱；
N是SIPI-409原料的XRPD图谱及其与苯磺酸反应产物的XRPD图谱。
图16是SIPI-409硫酸盐晶体的单晶分子立体结构投影图。
图17为使用SIPI-409标准品获得的溶解度标准曲线；R值0.999932。
图18是SIPI-409各种盐衍生物晶体稳定性考察获得的XRPD图谱；其中，
A是SIPI-409磷酸盐的晶型的稳定性考察获得的XRPD图谱；
B是SIPI-409烟酸盐的晶型的稳定性考察获得的XRPD图谱；
C是SIPI-409乙醇酸盐的晶型的稳定性考察获得的XRPD图谱；
D是SIPI-409草酸盐的晶型的稳定性考察获得的XRPD图谱；
E是SIPI-409乳清酸盐的晶型的稳定性考察获得的XRPD图谱；
F是SIPI-409苯磺酸盐的晶型的稳定性考察获得的XRPD图谱；
G是SIPI-409硫酸盐的晶型的稳定性考察获得的XRPD图谱。
具体实施方式
发明人经过广泛而深入的研究，发现结构如式Ⅰ所示的的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉盐衍生物在水中的溶解度较现有SIPI-409及SIPI-409盐酸盐有了显著的提高，更进一步的药代动力学实验表明本发明的SIPI-409的盐衍生物的生物利用度较现有的SIPI-409盐酸有了显著改善，以磷酸盐为例，其生物利用度较现有的SIPI-409盐酸盐可提高329％。
本发明提供了一种如式(I)所示的化合物SIPI-409的盐衍生物。
Figure PCTCN2017099549-appb-000003
其中，与SIPI-40成盐的可以是常见的有机酸或无机酸；可选自表1中所述的酸。
表1
Figure PCTCN2017099549-appb-000004
Figure PCTCN2017099549-appb-000005
采用XRPD对盐型初筛实验的结果进行测试，将SIPI-409与盐酸、丁二酸、反丁烯二酸、L-酒石酸、乙二磺酸、乙醇酸、乳清酸、DL-苹果酸、氢溴酸、草酸、磷酸、烟酸、硫酸、苯磺酸等反应后的XRPD图谱与SIPI-409原料的XRPD图谱进行比较，结果见附图15。结果显示上述14种反应产物的XRPD图谱在衍射图形，衍射角位置及衍射强度均与SIPI-409存在显著差异，可初步判断上述14种酸与SIPI-409发生了成盐反应。优选磷酸、硫酸、烟酸、草酸、乙醇酸、苯磺酸、或乳清酸与SIPI-409成盐；更优选硫酸、磷酸、烟酸、或草酸。
本发明提供的SIPI-409磷酸盐晶体，其中SIPI-409与磷酸比例为1:1，2:1或3:1，当SIPI-409与磷酸比例为1:1时，获得晶体使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：4.6±0.2°、7.6±0.2°、9.8±0.2°、10.2±0.2°、13.9±0.2°、14.4±0.2°、15.3±0.2°、18.1±0.2°、16.8±0.2°、20.5±0.2°、20.9±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.3±0.2°、27.1±0.2°； 更优选地，其XRPD图谱如图1所示。
上述SIPI-409磷酸盐晶体使用差示扫描量热技术分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在201±5℃处；更优选地，其DSC图谱如图2所示。
本发明提供的SIPI-409硫酸盐晶体，其中SIPI-409与硫酸比例为1:1，2:1，其中当SIPI-409与硫酸比例为1:1时，获得晶体使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：4.9±0.2°、7.1±0.2°、8.4±0.2°、9.7±0.2°、12.0±0.2°、15.4±0.2°、17.0±0.2°、19.5°±0.2°、20.3±0.2°、20.9±0.2°、21.6±0.2°、22.8±0.2°、23.6±0.2°、24.6±0.2°、25.4±0.2°、26.0±0.2°、30.8±0.2°；更优选地，其XRPD图谱如图3所示。
上述SIPI-409硫酸盐晶体，使用差示扫描量热技术(DSC)分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在130±5℃处；更优选地，其DSC图谱如图4所示。
上述SIPI-409硫酸盐晶体(C25H28N2O4S·H2SO4)的单晶为无色透明块状，晶体密度1.361g/cm3，空间群为P-1，晶胞参数：
Figure PCTCN2017099549-appb-000006
Figure PCTCN2017099549-appb-000007
α＝94.86°，β＝106.70°，γ＝110.95°，晶胞体积
Figure PCTCN2017099549-appb-000008
晶胞内不对称单位数Z＝2。(附图16)
本发明提供的SIPI-409烟酸盐晶体，使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：5.0±0.2°、5.9±0.2°、7.2±0.2°、8.2±0.2°、10.9±0.2°、12.2±0.2°、13.4±0.2°、14.4°±0.2°、15.1±0.2°、15.5±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.9±0.2°、20.5±0.2°、20.8±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.8±0.2°、25.1±0.2°、25.6±0.2°、27.0±0.2°、27.6±0.2°；更优选地，其XRPD图谱如图5所示。
本发明提供的SIPI-409烟酸盐晶体，使用差示扫描量热技术(DSC)分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在152±5℃处；更优选地，其DSC图谱如图6所示。
本发明提供的SIPI-409草酸盐晶体，其中SIPI-409与草酸比例为1:1或2:1，其中当SIPI-409与草酸比例为1:1时，获得晶体使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：3.4±0.2°、4.6±0.2°、5.5±0.2°、7.8±0.2°、9.2±0.2°、10.2±0.2°、10.8±0.2°、11.9°±0.2°、13.1±0.2°、13.8±0.2°、14.6±0.2°、16.4±0.2°、17.0±0.2°、18.4±0.2°、19.0±0.2°、20.2±0.2°、 21.9±0.2°、23.6±0.2°、25.8±0.2°、27.3±0.2°、30.0±0.2°、31.9±0.2°；更优选地，其XRPD图谱如图7所示。
上述SIPI-409草酸盐晶体，使用差示扫描量热技术(DSC)分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在161±5℃处，且在190～210℃范围存在一个较宽的吸热峰；更优选地，其DSC图谱如图8所示。
本发明提供的SIPI-409乙醇酸盐晶体，使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：4.7±0.2°、7.5±0.2°、9.9±0.2°、10.3±0.2°、13.7±0.2°、14.3±0.2°、14.9±0.2°、15.3°±0.2°、16.1±0.2°、16.9±0.2°、17.6±0.2°、18.1±0.2°、18.9±0.2°、19.3±0.2°、20.4±0.2°、20.8±0.2°、21.8±0.2°、22.5±0.2°、22.9±0.2°、24.3±0.2°、24.9±0.2°、25.3±0.2°、25.9±0.2°、27.7±0.2°；更优选地，其XRPD图谱如图9所示。
本发明提供的SIPI-409乙醇酸盐晶体，使用差示扫描量热技术(DSC)分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在187±5℃处；更优选地，其DSC图谱如图10所示。
本发明提供的SIPI-409苯磺酸盐晶体，使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：6.1±0.2°、6.8±0.2°、8.2±0.2°、8.8±0.2°、11.5±0.2°、12.7±0.2°、14.4±0.2°、15.0°±0.2°、15.5±0.2°、16.5±0.2°、17.0±0.2°、17.4±0.2°、17.7±0.2°、18.7±0.2°、19.4±0.2°、19.8±0.2°、20.3±0.2°、21.3±0.2°、21.7±0.2°、22.6±0.2°、23.0±0.2°、23.5±0.2°、24.2±0.2°、29.1±0.2°；更优选地，其XRPD如图11所示。
本发明提供的SIPI-409苯磺酸盐晶体，使用差示扫描量热技术(DSC)分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在150±5℃处，且在160℃附近存在一个肩峰；更优选地，其DSC图谱如图12所示。
本发明提供的SIPI-409乳清酸盐晶体，使用粉末X-射线衍射分析，采用Cu靶辐射光源实验条件时，其2θ特征衍射峰为：5.8±0.2°、8.7±0.2°、9.9±0.2°、11.2±0.2°、12.5±0.2°、13.9±0.2°、14.1±0.2°、15.2°±0.2°、16.2±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.0±0.2°、20.4±0.2°、21.9±0.2°、23.5±0.2°、24.0±0.2°、24.9±0.2°、25.9±0.2°、27.6±0.2°、29.5±0.2°、31.0±0.2°、31.4±0.2°；更优选地，其XRPD图谱如图13所示。
本发明提供的SIPI-409乳清酸盐晶体，使用差示扫描量热技术(DSC) 分析时，表现为升温速度为10℃/min的DSC图谱中存在一个吸热峰在138±5℃处；更优选地，其DSC图谱如图14所示。
本发明涉及的SIPI-409盐衍生物晶体包括单晶，也包括其多晶型。
本发明还提供了SIPI-409的盐衍生物及其晶体的制备方法，是将SIPI-409溶解在有机溶剂中，加入有机或无机酸，搅拌反应后，冷却析晶，得到SIPI-409的盐衍生物晶体。上述所述的溶剂包括醇类溶剂，酮类溶剂，醚类溶剂，酯类溶剂，芳烃类溶剂，和腈类溶剂。所述醇类溶剂包括甲醇，乙醇，和异丙醇；优选甲醇；所述酮类溶剂包括丙酮和2-丁酮；所述醚类溶剂包括甲叔醚，四氢呋喃，和2甲基四氢呋喃；所述酯类溶剂包括乙酸乙酯，乙酸甲酯，和乙酸异丙酯；所述芳烃类溶剂包括甲苯和二甲苯；所述腈类溶剂为乙腈。成盐的反应温度为0-80℃；优选10-60℃；最优选为40℃。SIPI-409与酸的比例及加料方式可以根据所需盐的衍生物而做适应性的变化，并不脱离本发明的原理。
本发明提供的SIPI-409盐衍生物或其晶体具有一定稳定性，可作为活性成分开发口服剂型的抗心律失常药物供临床使用。常见的口服给药形式包括，普通片剂，胶囊，分散片，微丸等，上述剂型中所述的赋形剂，润滑剂，粘合剂等辅料均为该领域内常见的辅料。
本发明提到的上述特征，或实施例提到的特征可以任意组合。本案说明书所揭示的所有特征可与任何组合物形式并用，说明书中所揭示的各个特征，可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明，所揭示的特征仅为均等或相似特征的一般性例子。
本发明的主要优点在于：本发明提供的新SIPI-409的盐衍生物及其晶体，能明显提高其水溶性，进而提高其生物利用度和成药性。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。除非另外说明， 否则所有的百分数、比率、比例、或份数按重量计。本发明中的重量体积百分比中的单位是本领域技术人员所熟知的，例如是指在100毫升的溶液中溶质的重量。除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
本发明涉及的实验中XRPD图谱为采用Cu靶辐射光源实验条件下获得。
本发明涉及的实验中DSC图谱表现为升温速度为10℃/min的图谱。
本发明涉及的SIPI-40盐衍生物的稳定性是指在一定时间内，所述盐衍生物晶体对温度，湿度，光照稳定性以及吸湿性。
实施例1
SIPI-409磷酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，滴加1M的磷酸甲醇溶液1.3mL(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409磷酸盐白色固体粉末0.52g，收率86％，该晶体中SIPI-409：磷酸＝1:1，元素分析如表2。其XRPD图谱如图1所示，DSC图谱如图2所示。
表2元素分析：
分析项目 测定值/％ 理论值/％
C 66.17 66.35
H 6.15 6.24
N 6.22 6.19
S 7.02 7.09
样品元素分析测定值与理论值误差<0.3％。
实施例2
SIPI-409硫酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，滴加1M的硫酸甲醇溶液1.3mL(0.13mmol)，继续 保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409硫酸盐白色固体粉末0.54g，收率90％，该晶体中SIPI-409：硫酸＝1:1，单晶数据如附图。其XRPD图谱如图3所示，DSC图谱如图4所示。
实施例3
SIPI-409烟酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，加入0.16g烟酸(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409烟酸盐白色固体粉末0.49g，收率78％。其XRPD图谱如图5所示，DSC图谱如图6所示。
实施例4
SIPI-409草酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，加入草酸0.117g(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409草酸盐白色固体粉末0.50g，收率84％。其XRPD图谱如图7所示，DSC图谱如图8所示。
实施例5
SIPI-409乙醇酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，加入乙醇酸0.098g(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409乙醇酸盐白色固体粉末0.47g，收率81％。其XRPD图谱如图9所示，DSC图谱如图10所示。
实施例6
SIPI-409苯磺酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，加入苯磺酸0.205g(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409苯磺酸盐白色固体粉末0.57g，收率84％。其XRPD图谱如图11所示，DSC图谱如图12所示。
实施例7
SIPI-409乳清酸盐及晶体的制备
取SIPI-409 0.5g(0.11mmol)，置50mL烧瓶中，加入20mL甲醇溶剂，水浴温度控制在40℃，加入乳清酸一水合物0.226g(0.13mmol)，继续保持40℃搅拌2小时后，冷却至5～15℃析晶，过滤，得到SIPI-409乳清酸盐白色固体粉末0.52g，收率77％。其XRPD图谱如图13所示，DSC图谱如图14所示。
实施例8
水中溶解度的测定
采用液相色谱法对SIPI-409及其盐衍生物进行水中溶解度的测定。
主要实验步骤：配置浓度分别5g/mL、10g/mL、50g/mL、100g/mL、200g/mL的SIPI-409标准品制备标准曲线，结果见图17。
色谱条件：
色谱柱：Phenomenex Luna 5u C18(2)100A 4.6×200mm
检测波长：210nm
流动相：乙腈/磷酸盐缓冲溶液(0.68g/L磷酸二氢钾，三乙胺调pH为3.0)＝68/32
柱温：30℃
进样量：10L
保留时间：约6.3min
样品处理：将待测样品制成过饱和水溶液(悬浮液)，置30℃条件下震荡12h后，置超声仪中超声30s，过滤，稀释适当的倍数，进行HPLC分析。测试结果见表3。
表3水中的溶解度结果
Figure PCTCN2017099549-appb-000009
Figure PCTCN2017099549-appb-000010
结果表明，本发明的SIPI-409磷酸盐、SIPI-409硫酸盐、SIPI-409烟酸盐、SIPI-409草酸盐、SIPI-409乙醇酸盐、SIPI-409苯磺酸盐、SIPI-409乳清酸盐的水中溶解度较现有SIPI-409及SIPI-409盐酸盐的有了显著的提高。
实施例9
药代动力学研究
水中溶解度的测试结果显示，SIPI-409磷酸盐在水中溶解度较SIPI-409及SIPI-409盐酸盐有大幅度的提高，故进一步对SIPI-409磷酸盐进行的药代动力学研究，并与SIPI-409盐酸盐进行了比较。
实验方法
口服(PO)分别给予SIPI-409盐酸盐、SIPI-409磷酸盐，研究其各自在SD大鼠体内的药代动力学参数和生物利用度。采用液相色谱-质谱-质谱联用法测定不同时刻血浆中SIPI-409盐酸盐、SIPI-409磷酸盐的浓度。
数据处理
所得血药浓度数据采用药动学处理软件WinNonlin 5.2非房室模型计算相关药代动力学参数。
实验结果
SIPI-409盐酸盐、SIPI-409磷酸盐的初步药代动力学见表4。
表4SD大鼠单次口服给药后的主要药动学参数
Figure PCTCN2017099549-appb-000011
结果表明：SD大鼠静脉注射给予SIPI-409盐酸盐和SIPI-409磷酸盐晶型α的药代动力学参数基本相当。SD大鼠口服给予SIPI-409盐酸盐的生物利用度为24％，而SIPI-409磷酸盐的生物利用度为79％。即本发明的SIPI-409磷酸盐生物利用度较现有的SIPI-409盐酸盐提高了329％。
实施例10
稳定性考察
温度稳定性考察
将SIPI-409磷酸盐、烟酸盐、乙醇酸盐、草酸盐、乳清酸盐、苯磺酸盐、硫酸盐置60℃烘箱内，分别于0天，5天，10天，20天，30天取样进行XRPD测试。
湿度稳定性考察
将SIPI-409磷酸盐、烟酸盐、乙醇酸盐、草酸盐、乳清酸盐、苯磺酸盐、硫酸盐置92.5％RH(饱和KNO3)内，分别于0天，5天，10天，20天，30天取样进行XRPD测试。
光照稳定性考察
将SIPI-409磷酸盐、烟酸盐、乙醇酸盐、草酸盐、乳清酸盐、苯磺酸盐、硫酸盐置光照箱内，分别于0天，5天，10天，20天，30天取样进行XRPD 测试。
吸湿性考察
为了进一步了解样品的吸湿性情况，将SIPI-409磷酸盐、烟酸盐、乙醇酸盐、草酸盐、乳清酸盐、苯磺酸盐、硫酸盐置于动态水份吸附分析仪(DVS)中进行吸湿性考察。
稳定性考察结果见附图18和表5。
表5 7种SIPI-409盐型的评价结果
Figure PCTCN2017099549-appb-000012
结果表明，除了烟酸盐对热不稳定，在60℃高温条件下，5天即发生变化，其它盐衍生物不但在水中溶解性好，也表现了想到的稳定性；其中SIPI-409磷酸盐在水中溶解度最大，达到9.69mg/mL，且在高温、高湿、光照条件下均稳定，DVS显示最大吸湿量仅为0.7％。
以上所述仅为本发明的较佳实施例而已，并非用以限定本发明的实质技术内容范围，本发明的实质技术内容是广义地定义于申请的权利要求范围中，任何他人完成的技术实体或方法，若是与申请的权利要求范围所定义的完全相同，也或是一种等效的变更，均将被视为涵盖于该权利要求范围之中。

Claims (25)

  1. 式I所示的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物：
    Figure PCTCN2017099549-appb-100001
    所述盐衍生物在水中的溶解度不小于3.0nmol/mL或1.8mg/mL。
  2. 根据权利要求1所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，其中，HA选自硫酸、磷酸、烟酸、草酸、乙醇酸、苯磺酸、或乳清酸；X选自1/3、1/2、或1。
  3. 根据权利要求1或2所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物为晶体。
  4. 根据权利要求2所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，HA为硫酸；X选自1/2或1。
  5. 根据权利要求2所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，HA为草酸；X选自1/2或1。
  6. 根据权利要求4所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当X为1时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.9±0.2°、7.1±0.2°、8.4±0.2°、9.7±0.2°、12.0±0.2°、15.4±0.2°、17.0±0.2°、19.5°±0.2°、 20.3±0.2°、20.9±0.2°、21.6±0.2°、22.8±0.2°、23.6±0.2°、24.6±0.2°、25.4±0.2°、26.0±0.2°、30.8±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在130±5℃处。
  7. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当X为1、HA为磷酸时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.6±0.2°、7.6±0.2°、9.8±0.2°、10.2±0.2°、13.9±0.2°、14.4±0.2°、15.3±0.2°、18.1±0.2°、16.8±0.2°、20.5±0.2°、20.9±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.3±0.2°、27.1±0.2°。
  8. 根据权利要求7所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，所述晶体的X-粉末衍射图谱如图1所示。
  9. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当X为1、HA为磷酸时，所述晶体使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在201±5℃处。
  10. 根据权利要求9所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，所述晶体的DSC图谱如图2所示。
  11. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当HA为烟酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：5.0±0.2°、5.9±0.2°、7.2±0.2°、8.2±0.2°、10.9±0.2°、12.2±0.2°、13.4±0.2°、14.4°±0.2°、15.1±0.2°、15.5±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.9±0.2°、20.5±0.2°、20.8±0.2°、21.9±0.2°、23.1±0.2°、23.5±0.2°、24.8±0.2°、25.1±0.2°、25.6±0.2°、27.0±0.2°、27.6±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在152±5℃。
  12. 根据权利要求5所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基 -1,2,3,4-四氢异喹啉的盐衍生物，当X为1时，所述晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：3.4±0.2°、4.6±0.2°、5.5±0.2°、7.8±0.2°、9.2±0.2°、10.2±0.2°、10.8±0.2°、11.9°±0.2°、13.1±0.2°、13.8±0.2°、14.6±0.2°、16.4±0.2°、17.0±0.2°、18.4±0.2°、19.0±0.2°、20.2±0.2°、21.9±0.2°、23.6±0.2°、25.8±0.2°、27.3±0.2°、30.0±0.2°、31.9±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在在161±5℃处，且在190～210℃范围存在一个较宽的吸热峰。
  13. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当HA为乙醇酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：4.7±0.2°、7.5±0.2°、9.9±0.2°、10.3±0.2°、13.7±0.2°、14.3±0.2°、14.9±0.2°、15.3°±0.2°、16.1±0.2°、16.9±0.2°、17.6±0.2°、18.1±0.2°、18.9±0.2°、19.3±0.2°、20.4±0.2°、20.8±0.2°、21.8±0.2°、22.5±0.2°、22.9±0.2°、24.3±0.2°、24.9±0.2°、25.3±0.2°、25.9±0.2°、27.7±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在187±5℃处。
  14. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当HA为苯磺酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：6.1±0.2°、6.8±0.2°、8.2±0.2°、8.8±0.2°、11.5±0.2°、12.7±0.2°、14.4±0.2°、15.0°±0.2°、15.5±0.2°、16.5±0.2°、17.0±0.2°、17.4±0.2°、17.7±0.2°、18.7±0.2°、19.4±0.2°、19.8±0.2°、20.3±0.2°、21.3±0.2°、21.7±0.2°、22.6±0.2°、23.0±0.2°、23.5±0.2°、24.2±0.2°、29.1±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在150±5℃处，且在160℃附近存在一个肩峰。
  15. 根据权利要求3所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，当HA为乳清酸时的晶体的晶型通过X-粉末衍射技术(XRPD)测定并以布拉格2θ角(Bragg 2-Theta)表征如下：5.8±0.2°、8.7±0.2°、9.9±0.2°、11.2±0.2°、12.5±0.2°、13.9±0.2°、14.1±0.2°、15.2°±0.2°、16.2±0.2°、17.0±0.2°、17.4±0.2°、17.8±0.2°、18.7±0.2°、19.0±0.2°、20.4±0.2°、 21.9±0.2°、23.5±0.2°、24.0±0.2°、24.9±0.2°、25.9±0.2°、27.6±0.2°、29.5±0.2°、31.0±0.2°、31.4±0.2°；或使用差示扫描量热技术(DSC)分析时，DSC图谱中存在一个吸热峰在138±5℃处。
  16. 根据权利要求1-15任一项所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其包括：将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉与相应的酸HA反应形成盐衍生物。
  17. 根据权利要求16所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其包括：将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉与相应的酸在有机溶剂中反应形成盐衍生物。
  18. 根据权利要求17所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其包括：HA为烟酸、草酸、乙醇酸、苯磺酸、或乳清酸时，将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉溶解于有机溶剂，然后加入相应的酸，冷却后析晶得产物。
  19. 根据权利要求17所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其包括：当HA为硫酸或磷酸时，将1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉溶解于有机溶剂，然后加入含有相应酸的有机溶剂，冷却后析晶得产物。
  20. 根据权利要求18或19所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其还包括：将析出的结晶或沉淀洗涤、干燥。
  21. 根据权利要求16-20任一项所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其特征在于，所述反应的反应温度为0-80℃。
  22. 根据权利要求17-20任一项所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其特征在于，所述有机溶剂为甲醇、乙醇、异丙醇、丙酮、2-丁酮、乙酸甲酯、乙酸异丙脂、甲叔醚乙腈、或甲苯。
  23. 根据权利要求21所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物的制备方法，其特征在于，HA为磷酸时，所述反应温度为10-60℃；优选为40℃。
  24. 一种药物组合物，由有效量的权利要求1-15任一项所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物和一种或多种药学上可接受的辅料组成。
  25. 一种权利要求1-15任一项所述的1-(3-甲磺酰胺基苄基)-6-甲氧基,7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物，在制备抗心律失常的药物中的应用。
PCT/CN2017/099549 2016-08-31 2017-08-30 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用 WO2018041112A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP17845414.6A EP3508478B1 (en) 2016-08-31 2017-08-30 Salt derivative of tetrahydroisoquinoline and crystalline thereof and preparation method therefor and application thereof
KR1020197009017A KR102346338B1 (ko) 2016-08-31 2017-08-30 테트라하이드로이소퀴놀린의 염 유도체 및 그 결정체의 제조방법과 응용
US16/329,685 US10676442B2 (en) 2016-08-31 2017-08-30 Salt derivative of tetrahydroisoquinoline and crystalline thereof and preparation method therefore and application thereof
JP2019512752A JP6823714B2 (ja) 2016-08-31 2017-08-30 テトラヒドロイソキノリンの塩の結晶、当該結晶を含んだ医薬組成物及び当該結晶の製造方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610786957.2 2016-08-31
CN201610786945.XA CN107793356B (zh) 2016-08-31 2016-08-31 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用
CN201610786945.X 2016-08-31
CN201610786957.2A CN107778232B (zh) 2016-08-31 2016-08-31 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用

Publications (1)

Publication Number Publication Date
WO2018041112A1 true WO2018041112A1 (zh) 2018-03-08

Family

ID=61301254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/099549 WO2018041112A1 (zh) 2016-08-31 2017-08-30 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用

Country Status (5)

Country Link
US (1) US10676442B2 (zh)
EP (1) EP3508478B1 (zh)
JP (1) JP6823714B2 (zh)
KR (1) KR102346338B1 (zh)
WO (1) WO2018041112A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166369A1 (zh) 2021-02-02 2022-08-11 江苏康缘药业股份有限公司 一种化合物晶型及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456639B (zh) * 2020-03-31 2024-01-26 江苏康缘药业股份有限公司 一种抗心律失常的药物组合物及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1566098A (zh) * 2003-07-02 2005-01-19 上海医药工业研究院 一类异喹啉化合物及其盐的制备方法和应用
CN101619038A (zh) * 2008-07-04 2010-01-06 上海医药工业研究院 一类异喹啉化合物或其盐及药物组合物、制备方法和应用
CN104693115A (zh) * 2013-12-06 2015-06-10 上海医药工业研究院 手性四氢异喹啉的衍生物或其盐及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1566098A (zh) * 2003-07-02 2005-01-19 上海医药工业研究院 一类异喹啉化合物及其盐的制备方法和应用
CN101619038A (zh) * 2008-07-04 2010-01-06 上海医药工业研究院 一类异喹啉化合物或其盐及药物组合物、制备方法和应用
CN104693115A (zh) * 2013-12-06 2015-06-10 上海医药工业研究院 手性四氢异喹啉的衍生物或其盐及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3508478A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166369A1 (zh) 2021-02-02 2022-08-11 江苏康缘药业股份有限公司 一种化合物晶型及其制备方法和应用

Also Published As

Publication number Publication date
KR20190040069A (ko) 2019-04-16
JP6823714B2 (ja) 2021-02-03
JP2019526594A (ja) 2019-09-19
EP3508478A1 (en) 2019-07-10
EP3508478B1 (en) 2022-12-21
US20190177277A1 (en) 2019-06-13
US10676442B2 (en) 2020-06-09
EP3508478A4 (en) 2020-04-22
KR102346338B1 (ko) 2022-01-03

Similar Documents

Publication Publication Date Title
WO2016184436A1 (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
DK1902029T3 (en) CRYSTALLINIC FORMS OF 4 - [(2,4-DICHLOR-5-METHOXYPHENYL) AMINO] -6-METHOXY-7- [3- (4-METHYL-1-PIPERAZINYL) PROPOXY] -3-QUINOLINCARBONITRIL AND PROCEDURES FOR PREPARATION
CN103974949B (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
WO2016124137A1 (zh) 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
WO2016110270A1 (zh) 来那替尼马来酸盐的新晶型及其制备方法
JP6971390B2 (ja) 重水素化ａｚｄ９２９１の結晶形、製造方法および使用
BR112019021447A2 (pt) sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica
JP2017530146A (ja) Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法
WO2011023146A1 (en) Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
WO2018041112A1 (zh) 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用
WO2020061996A1 (zh) 氘代azd9291化合物的新晶型及其用途
CN107778232B (zh) 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用
CA3035161A1 (en) Crystals of cyclic amine derivative and pharmaceutical use thereof
CN107793356B (zh) 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用
US8859567B2 (en) Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
DE60205504T2 (de) Zitronensäure salz von einer therapeutischen verbindung und deren pharmazeutischen zusammensetzungen
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
EP2649996A1 (en) Crystalline forms of sartans like telmisartan with beta blockers
TW201125861A (en) CDC7 inhibitor salts
WO2023078437A1 (zh) 一种肽硼酸类化合物新晶型及其制备方法
CN103819461B (zh) N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
WO2022247772A1 (zh) 一种含氧杂环化合物的晶型、其制备方法及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17845414

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019512752

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197009017

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017845414

Country of ref document: EP

Effective date: 20190401